simvastatin has been researched along with Lymphangiomyomatosis in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (75.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Courtwright, AM; Dorgan, D; Fleck, V; Kotloff, R; Kreider, M; Krymskaya, VP; McCormack, FX | 1 |
| Atochina-Vasserman, EN; Goncharov, DA; James, ML; Krymskaya, VP; Milavec, M; Volgina, AV | 1 |
| Jones, AM; Julien-Williams, PA; Moss, J; Stylianou, M; Taveira-DaSilva, AM | 1 |
| Albelda, SM; Colby, TV; Ducka, B; Fehrenbach, M; Goncharov, DA; Goncharova, EA; Haczku, A; Hino, O; Khavin, I; Krymskaya, VP; Merrilees, MJ | 1 |
1 trial(s) available for simvastatin and Lymphangiomyomatosis
| Article | Year |
|---|---|
A phase II clinical trial of the Safety Of Simvastatin (SOS) in patients with pulmonary lymphangioleiomyomatosis and with tuberous sclerosis complex.
Topics: Drug Therapy, Combination; Everolimus; Female; Forced Expiratory Volume; Humans; Lymphangioleiomyomatosis; Male; Safety; Simvastatin; Sirolimus; Treatment Outcome; Tuberous Sclerosis | 2020 |
3 other study(ies) available for simvastatin and Lymphangiomyomatosis
| Article | Year |
|---|---|
Statins in lymphangioleiomyomatosis. Simvastatin and atorvastatin induce differential effects on tuberous sclerosis complex 2-null cell growth and signaling.
Topics: Animals; Atorvastatin; Caspase 3; Cell Line; Cell Proliferation; Cell Shape; Dose-Response Relationship, Drug; Drug Synergism; Extracellular Signal-Regulated MAP Kinases; Heptanoic Acids; Humans; Lymphangioleiomyomatosis; Mechanistic Target of Rapamycin Complex 1; Mice; Multiprotein Complexes; Proto-Oncogene Proteins c-akt; Pyrroles; Signal Transduction; Simvastatin; Sirolimus; TOR Serine-Threonine Kinases; Transfection; Tuberous Sclerosis Complex 2 Protein; Tumor Suppressor Proteins | 2013 |
Retrospective review of combined sirolimus and simvastatin therapy in lymphangioleiomyomatosis.
Topics: Adult; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Follow-Up Studies; Forced Expiratory Volume; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunosuppressive Agents; Lung Neoplasms; Lymphangioleiomyomatosis; Male; Middle Aged; Respiratory Function Tests; Retrospective Studies; Simvastatin; Sirolimus; Treatment Outcome; Young Adult | 2015 |
Prevention of alveolar destruction and airspace enlargement in a mouse model of pulmonary lymphangioleiomyomatosis (LAM).
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; In Vitro Techniques; Lung Neoplasms; Lymphangioleiomyomatosis; Matrix Metalloproteinase 2; Matrix Metalloproteinase 3; Matrix Metalloproteinase 9; Mice; Mice, Nude; Simvastatin; Sirolimus; Tuberous Sclerosis Complex 1 Protein; Tuberous Sclerosis Complex 2 Protein; Tumor Suppressor Proteins; Vascular Endothelial Growth Factor D | 2012 |